Diabetes

Investigators found that there was no association of dementia incidence in insulin use at 5 years after stopping metformin and an association at 0.07 years for HbA1C level at year 1.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.

Preclinical studies and clinical trials have shown that both corticosteroids and VEGF inhibitors can be delivered as nanoparticles.

This “refreshing alternative” to calorie restriction does not include calorie counting, yet it is naturally associated with greater energy restriction compared to the latter.

However, uncomplicated diabetes was not significantly linked to a greater risk of all-cause mortality or death from colorectal cancer.

Semaglutide was found to be the most effective drug for weight loss, but the benefits may not outweigh the cost associated with treatment.

Long lasting weight reduction was reported in individuals that were treated with tirzepatide with diet and exercise, compared to placebo.

Twice-daily tenapanor tablets are recommended for patients with chronic kidney disease who are on dialysis, unresponsive or intolerant of any dose of a phosphate binder therapy.

SYNCHRONIZE-1, SYCHRONIZE-2, SYNCHRONIZE-CVOT will evaluate survodutide for overweight and obesity.

Harmful LDL functionality contributes to an increase of cardiovascular disease in those with obesity but could decrease within weight loss.

Investigators found that the adjusted mean change in A1C was –0.62% for dapagliflozin compared to 0.41% for a placebo in patients with type 2 diabetes.

Compared with sulfonylurea, these add-on treatments were also associated with fewer diabetes-related cardiovascular and renal complications as well as avoiding hypoglycemia.

Hispanic individuals have been found to be more likely to develop complications as a result of diabetes compared to those who are non-Hispanic White.

Investigators also found that rates of type 1 diabetes have been on the rise since 2016.

Chemotherapy, medication for attention deficit/hyperactivity disorder, glucagon-like peptide-1 agonists for weight loss and diabetes, and local anesthetics were among the drugs most affected by shortages.

Continuous glucose monitors can significantly improve the lives of patients with diabetes, offering less finger pokes, improved compliance, and easier use methods.

Insulin glargine-yfgn is more affordable than the reference product and patients do not require prescriber authorization switch.

Nuances can lead to frequent areas of confusion.

As a once-daily oral treatment, orforglipron could help address barriers to injectable medications, such as semaglutide and liraglutide.

Although GLP-1 receptor agonists have shown promise in promoting weight loss, they are prescription medications and should be used under the guidance of health care professionals.

Researchers have identified new uses for insulin sensitizers, including in the treatment of polycystic ovary syndrome and infertility.

Beyond its primary role in diabetes treatment, SGLT-2 inhibitors have demonstrated versatility in various health aspects, offering benefits beyond glucose reduction.

An upcoming large-scale clinical trial of the Glucose Everyday Matters program will evaluate its safety and efficacy in managing type 2 diabetes.

The risk of developing gestational diabetes was similar between both group prenatal care and traditional individual prenatal care, however, group care may benefit some patients as a treatment option.

The phase 3 study will advance the safety findings of survodutide reported in the phase 2 study to aid overweight and obesity.

Researchers recommended less restrictive policy regarding telepharmacies to improve access to medications and pharmacists, while ultimately improving outcomes and adherence to treatment regimens.